Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS

Trial Profile

A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Abrocitinib (Primary) ; Dabigatran etexilate
  • Indications Atopic dermatitis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 03 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
    • 30 Nov 2018 Planned End Date changed from 12 Feb 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top